Canaccord Genuity initiates coverage of Parabilis Medicines at Buy, sets price target at $39

Canaccord Genuity initiates coverage of Parabilis Medicines at Buy, sets price target at $39

Less than 1 min read

Canaccord Genuity initiated coverage of Parabilis Medicines at Buy and set a price target of $39.

The price target implies an upside of 36.7% from the Nov 6 close of $28.53.

Explore more price target data and ratings for Parabilis Medicines on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

Read the full article

Get unlimited access to analyst updates and every other article on TradingView.